R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C


This research paper assesses the impact of (i) incentives for R&D based on providing Intellectual Property (IP) rights protection, (ii) market competition and (iii) other factors including healthcare policies on access to direct acting antivirals (DAA) for hepatitis C in Europe.
UK, Rest of World